Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 5, 2011, Pages 829-835

  Tong, Myron John ^a,b   Hsu, Leeyen ^b   Chang, Patrick W ^b   Blatt, Lawrence Mitchell ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Albumin; Antiviral therapy; Basal core promoter mutant; Hepatocellular carcinoma; Liver related death; Platelet; Precore mutant

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; DRUG FATALITY; DRUG SCREENING; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 79954552745     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06623.x     Document Type: Article

References (32)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97-107.
2. Lok AS. Chronic hepatitis B. N. Engl. J. Med. 2002; 346: 1682-3.
3. Wilt TJ, Shamliyan T, Shaukat A etal. Management of chronic hepatitis B. Evidence report/technology assessment no. 174. Rockville, MD: Agency for Healthcare Research and Quality; 2008 Oct. AHRQ Publication No. 09-E002.
4. de Franchis R, Hadengue A, Lan G etal. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol. 2003; 39: S3-25.
5. Keeffe EB, Dieterich DT, Han SB etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. 2006; 4: 936-62.
6. ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006; 26: 47-58.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
8. Tong MJ, Hsien C, Hsu L etal. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48: 1070-8.
9. Marcellin P, Dusheiko G, Zoulim F etal. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
10. Keeffe EB, Dieterich DT, Han SB etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroeneterol. Hepatol. 2008; 6: 1315-41.
11. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
12. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
13. Tong MJ, Blatt LM, Kao JH etal. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J. Gastroenterol. 2006; 12: 6620-6.
14. Tong MJ, Hsien C, Song JJ etal. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig. Dis. Sci. 2009; 54: 1337-46.
15. De Jongh FE, Janssen HLA, De Man RA etal. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
16. Di Marco V, Lo Iacono O, Camma C etal. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-64.
17. Realdi G, Fattovich G, Hadziyannis S etal. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J. Hepatol. 1994; 21: 656-66.
18. Fattovich G. Natural course and prognosis of chronic hepatitis type B. J. Viral Hepatol. 1996; 2: 263-7.
19. Liaw YF, Tai DI, Chu CM etal. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-6.
20. Lo KJ, Tong MJ, Chien MC etal. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J. Infect. Dis. 1982; 146: 205-10.
21. Weissberg JI, Andres LL, Smith CI etal. Survival in chronic hepatitis B: an analysis of 279 patients. Ann. Intern. Med. 1984; 101: 613-16.
22. Taylor BC, Yuan JM, Shamliyan TA etal. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology 2009; 45: S85-95.
23. Wong VW, Chan SL, Mo F etal. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J. Clin. Oncol. 2010; 28: 1660-5.
24. Han SH, Durazo FA, Saab S etal. A proposed, evidence-based approach to the treatment of chronic hepatitis B. J. Clin. Gastroenterol. 2011; 45: 259-66.
25. Tong MJ, Blatt LM, Kao JH etal. Basal core promoter T1762/A1764 and precore A1896 gene mutations in HBsAg-positive hepatocellular carcinoma: a comparison to chronic carriers. Liver Int. 2007; 73: 1478-85.
26. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
27. Iloeje UH, Yang HI, Su J etal. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
28. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
29. Papatheodoridis GV, Lampertico P, Manolakopoulos S etal. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 2010; 53: 348-56.
30. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
31. Tong MJ, Hsien C, Hsu L etal. Reply. Hepatology 2009; 49: 701-2.
32. Tong MJ, Nguyen MO, Tong LT etal. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin. Gastroenterol. Hepatol. 2009; 7: 889-93.